Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Rockland Immunochemicals acquires antibody line from 21st Century Biochemicals
May 2013
by Jeffrey Bouley  |  Email the author
SHARING OPTIONS:

GILBERTSVILLE, Pa.—Biotechnology company Rockland Immunochemicals Inc. has acquired the Epi-Plus antibody product line from 21st Century Biochemicals Inc., a Marlboro, Mass.-based developer of epigenetic and custom peptides and antibodies. Epi-Plus antibodies are multiassay validated, including dot-blot testing using modified peptide arrays, Western blots and chromatin immunoprecipitation. The antibodies are reputed to be the most well-validated antibodies available for research in epigenetics, a market that is expected to reach $8 billion by 2017.
 
"The acquisition of the Epi-Plus product line expands Rockland 's Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," Jim Fendrick, president and CEO of Rockland Immunochemicals, said in a statement.  
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.